UNIFAC
Fortaleza, Ceará, 60160140, Brazil
NCT Number: NCT02949089
This study intends to provide information on the safety and tolerability of repeated oral doses of ACH04. A phase I, single-center, first in human, open-label, dose escalation study of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best address the study goals.
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Fortaleza, Ceará, 60160140, Brazil
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The subjects will receive the study medication in each group
Time frame: up to 39 days
Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram
Ache Laboratorios Farmaceuticos S.A.
Industry
An Open Label, Dose Escalation Study of ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02875249
Diarrhea, Pathological Conditions, Signs and Symptoms
Nantes, France
View Trial DetailsNCT06268717
Abdominal Pain, Alpha-Gal Syndrome
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05933525
Diarrhea, Digestive System Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT07230821
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Del Mar, California, United States
View Trial Details